Medtronic has partnered with Novo Nordisk to offer digital solutions that will combine their respective technologies to help diabetic patients better manage their condition.
Under the non-exclusive collaboration, Medtronic’s continuous glucose monitoring (CGM) devices, including the Guardian Connect system, will integrate insulin dosing data from smart insulin pens currently in development with Novo Nordisk.
The aim is to allow patients, as well as their healthcare professionals and caregivers, to automatically track glucose monitoring and insulin dosing in a single solution.
The integrated glucose and insulin formation is expected to facilitate informed treatment decisions.
Medtronic diabetes group advanced insulin management division president Alejandro Galindo said: “We see incredible power in combining a variety of data points to drive insights that help people living with diabetes make more informed decisions around managing their glucose levels.
“Our new agreement with Novo Nordisk, the world’s largest producer of insulin, will streamline the sharing of two of the most important pieces of information, glucose measurements and insulin dosed. With this, Medtronic can further enhance our market-leading analytics and insights to help ease the burden of diabetes.”
The company is planning to introduce its NovoPen 6 and NovoPen Echo Plus smart insulin pens, as well as disposable, pre-filled injection solution next year.
The insulin pens will be available for use alongside Android and iOS devices. Medtronic’s Guardian Connect system will be updated to support these pens.
Novo Nordisk commercial strategy & corporate affairs executive vice-president Camilla Sylvest said: “Millions of people living with diabetes work to control their sugar levels and track their insulin injections every day. To help ease the hassle of diabetes management, we are excited to be partnering with Medtronic, the largest medical device company in the world.
“We now collaborate with all major CGM device producers, which means we can bring the benefits of smart insulin pens to even more people.”
Abbott has also announced a similar collaboration with Sanofi.
This alliance will see data sharing between Abbott’s FreeStyle Libre glucose monitoring mobile app and cloud software and Sanofi’s connected insulin pens, apps and cloud software, which are currently under development.